Biotech Week articles from July 2002

Biotech Week archives from July 2002

Oxford Biomedica and Imperial College announce breakthrough in gene therapy.
July 3, 2002... 2002 JUL 3 - (NewsRx.com & NewsRx.net) -- Oxford BioMedica plc (OXB) and researchers at Imperial College of Science and Technology, London (Imperial College) have achieved very efficient gene transfer to mouse embryos in utero. The...

ATRA helps maintain hemostasis.
July 3, 2002... 2002 JUL 3 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - In addition to its anticancer effects, all-trans-retinoic acid (ATRA) can help breast cancer patients maintain hemostasis before surgery, researchers in Italy...

Bioplex Corp. licenses microbead technology from Indiana University.
July 3, 2002... 2002 JUL 3 - (NewsRx.com & NewsRx.net) -- Bioplex Corp. said it secured an exclusive license to Indiana University technology for the synthesis of optically encoded microbeads and nanobeads for human health applications, including drug...

Collaboration with Aventis will result in development of flash version of Allegra.
July 3, 2002... 2002 JUL 3 - (NewsRx.com & NewsRx.net) -- Ethypharm, one of the world's leading drug delivery system companies, announced it has entered into a codevelopment and licensing agreement to develop a Flash version of Aventis' drug Allegra...

Novel genetic assay can reduce waiting period.
July 3, 2002... 2002 JUL 3 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - A novel genetic tuberculosis screen can reduce the time period needed for conclusive diagnosis, researchers in the United States report. Cathal E....

Hormone therapy with innovative delivery system available.
July 3, 2002... 2002 JUL 3 - (NewsRx.com & NewsRx.net) -- Sanofi-Synthelabo, Inc., announced the commercial availability of Eligard 7.5 mg (leuprolide acetate for injectable suspension), an innovative hormone therapy for the palliative treatment of advanced...

Aastrom applies to move to Nasdaq SmallCap market.
July 3, 2002... 2002 JUL 3 - (NewsRx.com & NewsRx.net) -- Aastrom Biosciences, Inc. (ASTM) submitted a request for approval from the Nasdaq Stock Market to transfer its listing from the National Market to the SmallCap Market. The change maintains Aastrom's...

Company reports first quarter 2002 results.
July 3, 2002... 2002 JUL 3 - (NewsRx.com & NewsRx.net) -- Akorn, Inc. (AKRNE) reported an increase in net sales and income for the first quarter of 2002. The company said net sales were $13,593,000 for the first quarter of 2002, as compared with...

Angiotech announces retirement of two senior officers.
July 3, 2002... 2002 JUL 3 - (NewsRx.com & NewsRx.net) -- Angiotech Pharmaceuticals, Inc., (ANPI) announced the retirement of Thomas S. Spencer, PhD, chief scientific officer, and David E. Hartnett, MSc, MBA, senior vice president of operations. Thomas...

Company reports net loss of $0.52 per share.
July 3, 2002... 2002 JUL 3 - (NewsRx.com & NewsRx.net) -- AnorMED, Inc., reported a net loss of $13,368,000 ($0.52 per common share) for the fiscal year ended March 31, 2002, compared with a net loss of $11,299,000 ($0.48 per common share) in fiscal 2001. For...

Oncophage receives orphan drug status.
July 3, 2002... 2002 JUL 3 - (NewsRx.com & NewsRx.net) -- Antigenics, Inc., (AGEN) announced that the U.S. Food and Drug Administration (FDA) has granted the company's personalized cancer vaccine Oncophage (HSPPC-96) orphan drug status for the treatment of...

Company announces drug discovery collaboration with Ferring Pharmaceuticals.
July 3, 2002... 2002 JUL 3 - (NewsRx.com & NewsRx.net) -- Arena Pharmaceuticals, Inc., (ARNA) announced the signing of a research and license agreement with Ferring Pharmaceuticals, Inc., a unit of privately held Ferring Holding S.A. The collaboration will...

Avonex may lose dominance to Rebif.
July 3, 2002... 2002 JUL 3 - (NewsRx.com & NewsRx.net) -- Decision Resources announced the release of its new report focusing on multiple sclerosis. Multiple sclerosis (MS) is the second most common cause (after trauma) of neurological disability in young and...

Orphan drug designation granted for SCID-Xl Technology.
July 3, 2002... 2002 JUL 3 - (NewsRx.com & NewsRx.net) -- Avax Technologies, Inc., (AVXT) announced that it has received Orphan Drug designation from the U.S. Food and Drug Administration for the SCID-Xl technology that is currently in development in France....

Patent issued for delivery of AAV vector to the bloodstream.
July 3, 2002... 2002 JUL 3 - (NewsRx.com & NewsRx.net) -- Avigen, Inc., (AVGN), the leader in AAV gene delivery technology, announced it has received another U.S. patent, further extending its adeno-associated virus (AAV) vector intellectual property position....

Company gets orphan drug status for Photofrin.
July 3, 2002... 2002 JUL 3 - (NewsRx.com & NewsRx.net) -- Axcan Pharma, Inc., filed a supplemental new drug application (sNDA) with the Food and Drug Administration, for the use of its photodynamic therapy (PDT), Photofrin (porfimer sodium), in the treatment...

New dosage of ursodiol approved in Canada.
July 3, 2002... 2002 JUL 3 - (NewsRx.com & NewsRx.net) -- Axcan Pharma, Inc., has received approval from the Therapeutic Products Directorate of Health Canada for the use of 500 mg tablets of URSO (ursodiol) in the treatment of cholestatic liver diseases. ...

Generic Nordette tablets approved.
July 3, 2002... 2002 JUL 3 - (NewsRx.com & NewsRx.net) -- Barr Laboratories, Inc. (BRL) announced that the U.S. Food and Drug Administration (FDA) has approved its application to manufacture and market a generic version of Wyeth Laboratories' Nordette Tablets...

Company launches new water + nutrients supplement.
July 3, 2002... 2002 JUL 3 - (NewsRx.com & NewsRx.net) -- A subsidiary of Baxter International, Inc., (BAX) launched Pulse, a line of water + nutrients supplements. Pulse products are the first dietary supplements of this type to be developed and marketed by...

Company announces 2002 second quarter loss.
July 3, 2002... 2002 JUL 3 - (NewsRx.com & NewsRx.net) -- Biopure Corp. (BPUR) reported a net loss for the second fiscal quarter ending April 30, 2002. For the quarter, the company reported a net loss of $12.7 million or $0.49 per common share, compared with a...

BioSpecifics Technologies Corp. adopts shareholder rights agreement.
July 3, 2002... 2002 JUL 3 - (NewsRx.com & NewsRx.net) -- BioSpecifics Technologies Corp. (BSTC), announced that its board of directors has adopted a shareholder rights agreement. The rights to purchase shares of its newly issued Series B Junior Participating...

Company agrees to acquire Enteric Medical Technologies.
July 3, 2002... 2002 JUL 3 - (NewsRx.com & NewsRx.net) -- Boston Scientific Corporation (BSX) announced that it has entered into a definitive agreement to acquire Enteric Medical Technologies, Inc., (EMT), a privately held company based in Foster City,...

German court rules Dendron products infringe Boston Scientific patents.
July 3, 2002... 2002 JUL 3 - (NewsRx.com & NewsRx.net) -- Boston Scientific Corporation (BSX) and the Regents of the University of California announced that the District Court of Dusseldorf, Germany has ruled that electrolytic detachable coil products...

CRYO-CELL announces acquisition by affiliate, CRYO-CELL Europe.
July 3, 2002... 2002 JUL 3 - (NewsRx.com & NewsRx.net) -- Cryo-Cell International, Inc. (CCEL) announced that its affiliate, Cryo-Cell Europe, N.V., Zutphen, the Netherlands has completed the acquisition of MainGen GmbH from Asta Medica AG, a subsidiary of...

Cel-Sci reports flat revenues for first quarter.
July 3, 2002... 2002 JUL 3 - (NewsRx.com & NewsRx.net) -- Cel-Sci Corp. (CVM) reports revenue for the quarter from January 1, 2002, until March 31, 2002, was $93,050 compared with $87,888 in the same quarter of last year. Revenues were derived from interest...

Alexander Chucholowski named executive director.
July 3, 2002... 2002 JUL 3 - (NewsRx.com & NewsRx.net) -- ChemBridge Research Laboratories, LLC (CRL) announces the appointment of Alexander Chucholowski, PhD as executive director of chemistry, and substantial expansion of its laboratory space. ...

Company reports net loss: $0.12 per common share.
July 3, 2002... 2002 JUL 3 - (NewsRx.com & NewsRx.net) -- Chromos Molecular Systems, Inc., (CHR) a global leader in the development and commercialization of chromosome-based technologies, announced first quarter results for the period ended March 31, 2002. ...

Additional funding added to clinical trials contract.
July 3, 2002... 2002 JUL 3 - (NewsRx.com & NewsRx.net) -- Covalent Group, Inc., (CVGR) announced the expansion of $1.3 million in new services to an on-going $6.3 million study, increasing the total value of the contract to $7.6 million. This study is for...

PER.C6 license signed with MedImmune.
July 3, 2002... 2002 JUL 3 - (NewsRx.com & NewsRx.net) -- Dutch antibody and vaccine company Crucell N.V. (CRXL) announced it has granted the U.S. biotechnology company MedImmune, Inc., (MEDI), an exclusive license to its proprietary human cell line PER.C6....

Company restructures, sells cryosurgical assets.
July 3, 2002... 2002 JUL 3 - (NewsRx.com & NewsRx.net) -- Cryomedical Sciences, Inc., (CRYM) has executed a definitive agreement to sell its cryosurgical product line and related intellectual property assets to Irvine, California-based Endocare, Inc. (ENDO)....

Company issues financial guidance, outlines strategic plan.
July 3, 2002... 2002 JUL 3 - (NewsRx.com & NewsRx.net) -- Cytogen Corporation (CYTO), a biopharmaceutical company with an established and growing product line in prostate cancer and a subsidiary involved in signal transduction pathway research, announced...

First quarter 2002 net loss: $0.79 per share.
July 3, 2002... 2002 JUL 3 - (NewsRx.com & NewsRx.net) -- DOV Pharmaceutical, Inc., (DOVP) announced its results for the first quarter ending March 31, 2002. For the first quarter of 2002, the company reported a net loss of $3.9 million, or $0.79 per...

Preliminary results of stock tender offer released.
July 3, 2002... 2002 JUL 3 - (NewsRx.com & NewsRx.net) -- DaVita, Inc., (DVA) announced the preliminary results of its modified Dutch auction tender offer for up to 15 million shares of its common stock at a range of $21.00 to $25.00 per share, net to the...

Company responds to request from FTC for additional information.
July 3, 2002... 2002 JUL 3 - (NewsRx.com & NewsRx.net) -- Digene Corporation (DIGE) announced that it has provided additional information and documentary material responsive to a request from the U.S. Federal Trade Commission for such material in connection...

Company announces plan for restructuring.
July 3, 2002... 2002 JUL 3 - (NewsRx.com & NewsRx.net) -- Emisphere Technologies, Inc. (EMIS) has initiated a restructuring plan intended to ensure current cash balances are sufficient to continue the advancement of all existing development programs, including...

First quarter net loss: $0.10 per share.
July 3, 2002... 2002 JUL 3 - (NewsRx.com & NewsRx.net) -- Forbes Medi-Tech, Inc., announced its financial results for its first quarter of fiscal 2002, being the 3-month period ended March 31, 2002. In 2001 the company changed its year-end from July 31 to...

Favorable verdict issued in patent litigation with Vysis.
July 3, 2002... 2002 JUL 3 - (NewsRx.com & NewsRx.net) -- Gen-Probe, Inc., announced that a jury has returned a favorable verdict in the company's lawsuit with Vysis, Inc., a wholly owned subsidiary of Abbott Laboratories, concerning U.S. Patent No. 5,750,338....

Letter of intent signed with Healthcare Management Company.
July 3, 2002... 2002 JUL 3 - (NewsRx.com & NewsRx.net) -- GenoMed, Inc., (GMED), a St. Louis, Missouri-based medical genomics biotechnology company, announced that it has signed a Letter of Intent to license its ACE inhibitor treatment regimen to the...

Genoptix adds Robert E. Curry to its board of directors.
July 3, 2002... 2002 JUL 3 - (NewsRx.com & NewsRx.net) -- Genoptix, Inc. announced the appointment of Robert E. Curry, PhD, to its Board of Directors. Curry is currently a Venture Partner at Sprout Group, a venture capital affiliate of Credit Suisse First...

$72M in equity purchase from Aventis received.
July 3, 2002... 2002 JUL 3 - (NewsRx.com & NewsRx.net) -- Genta, Inc., (GNTA) announced that it has received $72 million in gross proceeds from Aventis pursuant to a purchase of common stock, according to terms of the recently concluded collaboration for...

Company changes name.
July 3, 2002... 2002 JUL 3 - (NewsRx.com & NewsRx.net) -- Genzyme Transgenics Corporation has changed its name to GTC Biotherapeutics, Inc., and its Nasdaq ticker symbol to GTCB. "The change of our name to GTC Biotherapeutics brings clarity to our...

Federal district court rules in Augmentin patent trial; GSK to appeal ruling.
July 3, 2002... 2002 JUL 3 - (NewsRx.com & NewsRx.net) -- GlaxoSmithKline (GSK) announced that a federal judge in the United States Federal District Court for the Eastern District of Virginia has ruled in favor of Geneva Pharmaceuticals, Teva Pharmaceuticals...

Management team expanded, two corporate officers added.
July 3, 2002... 2002 JUL 3 - (NewsRx.com & NewsRx.net) -- Inhibitex, Inc., announced the hiring of Seth V. Hetherington, MD, as vice president of clinical affairs and chief medical officer, and David M. Wonnacott, PhD, as vice president quality and regulatory...

Renowned researchers to lead hepatitis research, development programs.
July 3, 2002... 2002 JUL 3 - (NewsRx.com & NewsRx.net) -- InterMune, Inc., (ITMN) announced that it has appointed Lawrence Blatt, PhD, and Brian Murphy, MD, to the newly created positions of vice president of biopharmacology research, and director, clinical...

Biotech backers confident about landing Genomics Consortium.
July 3, 2002... 2002 JUL 3 - (NewsRx.com & NewsRx.net) -- Leaders of Arizona's biotech task force say they're confident they have raised enough money to land an international biotech research center. Although they're $10 million short of the $100 million...

First profitable quarter reported: $0.01 per share.
July 3, 2002... 2002 JUL 3 - (NewsRx.com & NewsRx.net) -- International Isotopes, Inc., (INIS) announced financial results for the first quarter ended March 31, 2002. For the 3 months ended March 31, 2002, International Isotopes, Inc., earned $30,941 or...

Pivotal patent provides control over third-generation antisense chemistry.
July 3, 2002... 2002 JUL 3 - (NewsRx.com & NewsRx.net) -- Isis Pharmaceuticals, Inc., (ISIS) announced that the United States Patent and Trademark Office has issued U.S. Patent No. 6,395,474 to a group of inventors originally working at the University of...

Acquisition of Ortho-Prefest completed.
July 3, 2002... 2002 JUL 3 - (NewsRx.com & NewsRx.net) -- King Pharmaceuticals, Inc., (KG) announced the completion of the company's previously announced acquisition from Ortho-McNeil Pharmaceutical, Inc., a Johnson & Johnson subsidiary, of Ortho-Prefest...

Ken Heilbrunn named VP of clinical development.
July 3, 2002... 2002 JUL 3 - (NewsRx.com & NewsRx.net) -- La Jolla Pharmaceutical Company (LJPC) announced that it has appointed Kenneth R. Heilbrunn, MD to the position of vice president of clinical development. Heilbrunn will oversee clinical research,...

Lopinavir can enhance safety, efficacy of antiretroviral regimens.
July 10, 2002... 2002 JUL 10 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Researchers in the United States say that a novel HIV protease inhibitor could make a valuable addition to antiretroviral drug regimens. Dr. Akhteruzzaman...

Novel agent ZD6126 selective for vessels in tumor destruction.
July 10, 2002... 2002 JUL 10 - (NewsRx.com & NewsRx.net) -- by Sonia Nichols, senior medical writer - New findings in animal model experiments point to the novel vascular targeting agent ZD6126 as being selective for destroying tumor vessels in several...

Study shows Humalog Mix75/25 provides better blood sugar control over NPH.
July 10, 2002... 2002 JUL 10 - (NewsRx.com & NewsRx.net) -- by Lynn Yoffee, senior medical writer - People with type 2 diabetes who are treated with Humalog Mix75/25 (75% insulin lispro protamine suspension, 25% insulin lispro injection [rDNA origin]) achieve...

Line probe assay can predict treatment outcome.
July 10, 2002... 2002 JUL 10 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Researchers in Luxembourg have identified a new tool for predicting the outcome of antiretroviral treatment for HIV infection. Dr. Jean Servais and...

In-office urine test detects bladder cancer.
July 10, 2002... 2002 JUL 10 - (NewsRx.com & NewsRx.net) -- by Lynn Yoffee, senior medical writer - A new diagnostic test, which works much like a home pregnancy test, has been launched for use by physicians in office as an aid to support cystoscopy to detect...

Artificial pancreas is one step closer to reality.
July 10, 2002... 2002 JUL 10 - (NewsRx.com & NewsRx.net) -- by Lynn Yoffee, senior medical writer - An artificial pancreas has long been considered the Holy Grail of diabetes management, yet many patients and their physicians believe that it is decades away....

Mark Boulding named senior VP, business development and legal.
July 10, 2002... 2002 JUL 10 - (NewsRx.com & NewsRx.net) -- PTC Therapeutics, Inc., a privately held biopharmaceutical company, has appointed Mark Boulding as senior vice president, business development and legal. Boulding comes to PTC with broad experience...

Scott M. Horvitz promoted to chief financial officer.
July 10, 2002... 2002 JUL 10 - (NewsRx.com & NewsRx.net) -- 3-Dimensional Pharmaceuticals, Inc., (DDDP) announced that Scott M. Horvitz has been promoted to chief financial officer. Horvitz previously served as vice president, finance and administration...

Acquisition of Biocompatibles' Cardiovascular stent business completed.
July 10, 2002... 2002 JUL 10 - (NewsRx.com & NewsRx.net) -- Abbott Laboratories (ABT) announced that it has completed the acquisition of the cardiovascular stent business of Biocompatibles International plc for 164.7 million British pounds (approximately $234.5...

Companies enter strategic alliance for cardiovascular products.
July 10, 2002... 2002 JUL 10 - (NewsRx.com & NewsRx.net) -- Abbott Laboratories announced that it has entered into a worldwide agreement with Medtronic, Inc., to market Medtronic's proprietary next-generation stent delivery system as well as its current...

European license agreement announced for Zindaclin.
July 10, 2002... 2002 JUL 10 - (NewsRx.com & NewsRx.net) -- Access Pharmaceuticals, Inc., (AKC) announced that Strakan Group, Ltd., our worldwide licensee for ResiDerm, has signed a licensing agreement granting exclusive marketing rights for Zindaclin for...

Stock trading plans to expire.
July 10, 2002... 2002 JUL 10 - (NewsRx.com & NewsRx.net) -- Adolor Corporation (ADLR), a biopharmaceutical company specializing in pain management, announced that its board of directors has decided not to approve the renewal of predetermined plans for...

$15M secured to commercialize NanoMate technology.
July 10, 2002... 2002 JUL 10 - (NewsRx.com & NewsRx.net) -- Advion BioSciences, Inc., a privately held developer of automated, chip-based mass spectrometry tools and research-service provider to the pharmaceutical industry, announced a placement of Series B...

Strategic alliance with Pfizer targets multiple enzyme classes.
July 10, 2002... 2002 JUL 10 - (NewsRx.com & NewsRx.net) -- Affinium Pharmaceuticals announced a major strategic alliance with Pfizer Inc (PFE) for structure guided drug discovery for Pfizer therapeutic programs. The Pfizer-Affinium structure-centric...

$20M private placement financing complete.
July 10, 2002... 2002 JUL 10 - (NewsRx.com & NewsRx.net) -- Agennix, Inc., a closely held developer of protein and peptide-based drugs, announced it has completed a $20 million private placement financing. "The additional capital allows us to complete phase...

FDA approvable status granted for generic version of Neurontin.
July 10, 2002... 2002 JUL 10 - (NewsRx.com & NewsRx.net) -- Alpharma, Inc., announced that Purepac Pharmaceutical Co., a subsidiary of Alpharma, has received approvable status from the U.S. Food and Drug Administration (FDA) to manufacture and market gabapentin...

Financial results for first quarter 2002 released.
July 10, 2002... 2002 JUL 10 - (NewsRx.com & NewsRx.net) -- AltaRex Corp. (AXO, ALXFF.PK), a developer of foreign antibodies that activate the immune system to treat cancer, announced its financial results for the first quarter ended March 31, 2002. All...

Company exercises option to acquire U.S. rights to Permax.
July 10, 2002... 2002 JUL 10 - (NewsRx.com & NewsRx.net) -- Amarin Corporation plc (AMRN) announced that it has exercised its purchase option to acquire the remaining U.S. rights to Permax (pergolide mesylate) from Elan Pharmaceuticals, Inc. Following the...

Company announces new president, new appointment to the board.
July 10, 2002... 2002 JUL 10 - (NewsRx.com & NewsRx.net) -- American Biogenetic Sciences, Inc., (ABS) announced that James H. McLinden, PhD, senior vice president and chief scientific officer of the company since September 2000, has been appointed by the Board...

Approval granted for generic Benadryl injection.
July 10, 2002... 2002 JUL 10 - (NewsRx.com & NewsRx.net) -- American Pharmaceutical Partners (APPX) announced it has received approval from the U.S. Food and Drug Administration (FDA) for the abbreviated new drug application (ANDA) of diphenhydramine...

Tentative approval granted for anticancer compound carboplatin.
July 10, 2002... 2002 JUL 10 - (NewsRx.com & NewsRx.net) -- American Pharmaceutical Partners (APPX) announced it has received tentative approval from the U.S. Food and Drug Administration (FDA) of its abbreviated new drug application (ANDA) for carboplatin...

New members named to board of directors.
July 10, 2002... 2002 JUL 10 - (NewsRx.com & NewsRx.net) -- Amersham plc (AHM) announces the appointments to the board of directors of Andrew Carr as an executive director and professor Mathias Uhlen as a non-executive director, with immediate effect. Both...

Company reports first quarter net loss of $0.24 per share.
July 10, 2002... 2002 JUL 10 - (NewsRx.com & NewsRx.net) -- Amylin Pharmaceuticals, Inc., (AMLN) reported a net loss of $22.1 million, or $0.30 per share, for the first quarter ended March 31, 2002, compared with a net loss of $15.0 million, or $0.24 per share,...

Two SBIR grants will be used to help discover potential cancer drugs.
July 10, 2002... 2002 JUL 10 - (NewsRx.com & NewsRx.net) -- AnVil, a pioneering life sciences discovery company that turns data into decision-quality knowledge, announced that it has been awarded two Small Business Innovation Research (SBIR) grants from the...

NCI contract awarded for manufacturing, formulation of natural anticancer drug.
July 10, 2002... 2002 JUL 10 - (NewsRx.com & NewsRx.net) -- Aphios Corporation has been awarded phase II of a Fast Track SBIR contract entitled "SuperFluids Isolation of Natural Anticancer Drugs" from the National Cancer Institute (NCI), National Institutes of...

First quarter net losses reported at $0.01 per share.
July 10, 2002... 2002 JUL 10 - (NewsRx.com & NewsRx.net) -- AutoImmune, Inc., (AIMM) reported a net loss of $0.22 million, or $0.01 per share basic and diluted, for the 3 months ended March 31, 2002, compared with a net loss of $0.12 million, or $0.01 per share...

Avanir's docosanol cream approved for marketing in Israel, Korea, and Canada.
July 10, 2002... 2002 JUL 10 - (NewsRx.com & NewsRx.net) -- Avanir Pharmaceuticals (AVN) announced that the Ministry of Health in Israel has approved the company's docosanol 10% cream for marketing as a topical treatment for cold sores. Docosanol 10% cream...

Marketing approval sought for Docosanol 10% cream.
July 10, 2002... 2002 JUL 10 - (NewsRx.com & NewsRx.net) -- Avanir Pharmaceuticals (AVN) announced that it filed for marketing approval for docosanol 10% cream in Europe in a submission to the Medical Products Agency (MPA) in Sweden. Avanir expects the MPA's...

Patents protecting Remeron SolTab challenged.
July 10, 2002... 2002 JUL 10 - (NewsRx.com & NewsRx.net) -- Barr Laboratories, Inc., (BRL) announced that it has been sued by Akzo Nobel and Organon, Inc., which initiates Barr's challenge of Akzo's patent protecting Remeron SolTab orally disintegrating tablets...

Seasonale oral contraceptive phase III trial results subject of ACOG poster session.
July 10, 2002... 2002 JUL 10 - (NewsRx.com & NewsRx.net) -- Barr Laboratories, Inc., (BRL) presented an initial review of the primary efficacy and safety data from its recently completed phase III clinical trial for its Seasonale extended oral contraceptive....

Bhaskar Chaudhuri succeeds Gordon J. Dow as president and CEO.
July 10, 2002... 2002 JUL 10 - (NewsRx.com & NewsRx.net) -- After 25 years under the guidance of Dr. Gordon J. Dow, its founder, Dow Pharmaceutical Sciences named Bhaskar Chaudhuri, PhD, as president and CEO. Chaudhuri comes to Dow with more than 20 years'...

Study: Panzem safe with prolonged stable disease and clinical benefit.
July 10, 2002... 2002 JUL 10 - (NewsRx.com & NewsRx.net) -- EntreMed, Inc., (ENMD) a company focused on angiogenesis research and product development, released additional phase I data demonstrating that Panzem is well tolerated and stabilized disease for...

Roche and Genmab expands antibody collaboration.
July 10, 2002... 2002 JUL 10 - (NewsRx.com & NewsRx.net) -- Roche and Genmab A/S announced a broad expansion of their current collaboration for the creation and development of human antibody therapeutic products for life-threatening and debilitating diseases....

Lorus' gene therapy program demonstrates anticancer potential for colon cancer.
July 10, 2002... 2002 JUL 10 - (NewsRx.com & NewsRx.net) -- Lorus Therapeutics, Inc., announced data demonstrating the potential of its R1 tumor suppressor for the treatment of cancer. The results, which support the company's emerging gene therapy...

Kevin Corcoran becomes new president and CEO.
July 10, 2002... 2002 JUL 10 - (NewsRx.com & NewsRx.net) -- Lynx Therapeutics, Inc., (LYNX) announced that Kevin Corcoran has been promoted to president and CEO of Lynx. Corcoran has served as Lynx's vice president, operations, for the past 3 years. ...